Teva Company Profile

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has seven hundred and thirty-eight approved drugs.

There are one hundred US patents protecting TEVA drugs. There are fifty-three tentative approvals on TEVA drugs.

There are nine hundred and twenty-two patent family members on TEVA drugs in forty-nine countries and one thousand and seventy-six supplementary protection certificates in eighteen countries.

Summary for Teva

International Patents:	922
US Patents:	100
Tradenames:	510
Ingredients:	445
NDAs:	738
Patent Litigation for Teva:	See patent lawsuits for Teva
PTAB Cases with Teva as petitioner:	See PTAB cases with Teva as petitioner

Drugs and US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	CLONAZEPAM	clonazepam	TABLET;ORAL	074569-003	Sep 10, 1996	AB	RX	No	No
Teva Parenteral	BLEOMYCIN SULFATE	bleomycin sulfate	INJECTABLE;INJECTION	064084-002	Jun 1, 1996		DISCN	No	No
Teva	MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; moexipril hydrochloride	TABLET;ORAL	076980-001	Mar 7, 2007	AB	RX	No	No
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-003	Apr 28, 2023		RX	Yes	No	8,741,327		Y

Expired US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,342,476
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-005	Feb 20, 2020	6,871,646
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-002	Jan 27, 2017	6,701,917
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017	6,446,627

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	for Injection	200 mcg/vial		2015-05-01
	for Injection	3.5 mg/vial		2016-10-26
	Tablets	0.5 mg and 1 mg		2010-05-17
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10
	for Injection	100 mcg/vial and 500 mcg/vial		2015-04-14
	Tablets	1 mg/0.02 mg and 75 mg		2006-04-17
	Delayed-release Tablets	20 mg		2015-06-03

Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for Teva Drugs

Country	Patent Number	Estimated Expiration
Serbia	53885
Slovenia	2692341
South Korea	20230003308
Japan	7419571

Supplementary Protection Certificates for Teva Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454511	99C0009	Belgium		PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
1744764	2018/042	Ireland		PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180823
1853250	37/2014	Austria		PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230
1532149	PA2012022	Lithuania		PRODUCT NAME: LINAGLIPTINUM + METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/12/780/001 - EU/1/12/780/034 20120720

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm